The FDA has granted Orphan Drug designation to ersodetug (RZ358) for the treatment of hypoglycemia due to tumor hyperinsulinism.
In a report released on December 3, Julian Harrison from BTIG maintained a Buy rating on Rezolute (RZLT – Research Report), with a price target ...
for the treatment of post-bariatric hypoglycemia (PBH). LUCIDITY is designed to evaluate the FDA-agreed upon primary outcome of reduction in hypoglycemia events and to have similar inclusion and ...
MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of ...
Angie Brown, Quinnipiac University Knee injuries are common in athletes, accounting for 41% of all athletic injuries. But knee injuries aren’t limited to competitive athletes. In our everyday lives, ...
AOP Orphan Pharmaceuticals GmbH (AOP Health), based in Vienna, Austria, announced that the U.S. Food and Drug Administration ...
UI Health has announced it is the exclusive provider of an FDA-approved therapy for the most critical form of Type 1 diabetes ...
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ ...
News Medical on MSN18d
New therapy from UI Health becomes the first FDA-approved treatment for brittle type 1 diabetesA new therapy for brittle type 1 diabetes, the only treatment currently approved by the U.S. Food and Drug Administration, is ...
Neonatal diabetes, a hereditary disease causing high blood sugar in newborns, requires comprehensive care from various ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback